Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

09 Janurary 2024

Alphamab Oncology Announced Innovative Bispecific Antibody Coupling Drug JSKN016 Clinical Study Accepted by CDE JSKN016 is a bispecific antibody conjugated drug (ADC) targeting HER3 and TROP2
11 December 2023

Alphamab's Novel Subcutaneous Anti-HER2 Bispecific ADC JSKN033 Approved for Clinical Studies in Australia JSKN033 is a subcutaneous injection compound consisting of JSKN003 and envafolimab
07 December 2023

Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer KN026 in combination with docetaxel is well tolerated and has shown promising clinical benefit as 1L treatment for HER2-positive BC
04 December 2023

First Patient Dosed in Phase Ⅲ Study of JSKN003 for the Treatment of Advanced HER2-Low Breast Cancer is a phase III clinical study in patients with unresectable locally advanced or metastatic HER2 low-expressing breast cancer
07 November 2023

KN026 was Granted Breakthrough Therapy Designation by CDE KN026 is expected to become the first anti-HER2 treatment for second-line gastric cancer where HER2-targeted therapy has failed.
24 October 2023

Alphamab Oncology updated data from two studies of KN026 in combination with docetaxel for HER2-positive breast cancer at ESMO the results of two studies of HER2 bispecific antibody KN026 were presented at the European Society of Medical Oncology (ESMO) Annual Meeting
24 October 2023

Alphamab Oncology Announces New Data from Multiple Studies of KN046 with Lung Cancer and Thymic Carcinoma at ESMO the results of four studies of PD-L1/CTLA-4 bispecific antibody KN046 were presented at the European Society of Medical Oncology (ESMO) Annual Meeting
10 August 2023

Alphamab Oncology will update the research results of several core pipeline products at the 2023 ESMO Annual Meeting posters will be announce at the 2023 European Society for Medical Oncology (ESMO) Congress.
10 July 2023

The Results of Phase II Clinical Study of KN046 in NSCLC were published in European Journal of Cancer KN046 showed promising efficacy and favorable safety profile in advanced squamous and non-squamous NSCLC patients after failure of or intolerance to previous platinum-based chemotherapy.
07 June 2023

The Results of Phase I Clinical Study of KN046 were published in Journal for ImmunoTherapy of Cancer the phase I clinical research results of KN046 in advanced solid tumor

5 6 7 8 9 10 11